Alliance Pharma Plc Rating Lowered to Hold at Numis Securities Ltd (APH)
Alliance Pharma Plc (LON:APH) was downgraded by stock analysts at Numis Securities Ltd to a “hold” rating in a report issued on Tuesday, ARN reports. They currently have a GBX 38 ($0.63) price objective on the stock, down from their previous price objective of GBX 41 ($0.68). Numis Securities Ltd’s price target indicates a potential downside of 0.98% from the stock’s previous close.
APH has been the subject of a number of other recent research reports. Analysts at Investec downgraded shares of Alliance Pharma Plc to a “sell” rating in a research note to investors on Tuesday. They now have a GBX 30 ($0.49) price target on the stock, down previously from GBX 33 ($0.54). Separately, analysts at FinnCap reiterated a “hold” rating on shares of Alliance Pharma Plc in a research note to investors on Tuesday. They now have a GBX 38.50 ($0.63) price target on the stock. Finally, analysts at FinnCap reiterated a “hold” rating on shares of Alliance Pharma Plc in a research note to investors on Wednesday, December 18th. They now have a GBX 38.50 ($0.63) price target on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company. The company presently has an average rating of “Hold” and an average target price of GBX 35.42 ($0.58).
Alliance Pharma Plc (LON:APH) opened at 37.00 on Tuesday. Alliance Pharma Plc has a 1-year low of GBX 31.45 and a 1-year high of GBX 40.50. The stock has a 50-day moving average of GBX 37.6 and a 200-day moving average of GBX 35.53.
Alliance Pharma plc is engaged in the acquisition, marketing and distribution of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.